Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study

Abstract

Introduction:The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy.Methods: In this phase III, open-label, multicenter study, 254 adults with stable CAD having uncontrolled hypertension despite being treated with FDC of metoprolol (25/50 mg) and telmisartan (40 mg) were included. Patients received either of the following FDC for 24 weeks: metoprolol (25 mg), telmisartan (40 mg), and chlorthalidone (12.5 mg) (FDC1; n = 139) or metoprolol (50 mg), telmisartan (40 mg), and chlorthalidone (12.5 mg) (FDC2; n = 115) tablets once daily. The FDCs were developed using the novel Wrap Matrix TM

Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double‐blind, active‐controlled, multicenter phase 3 trial

“…Most of the studies regarding combination therapy prefer lower dose of chlorthalidone as 3.125-12.5 mg combination in dual 25 or triple therapy. [26][27][28][29] Safety results of our study regarding triple combination therapy including chlorthalidone 25 mg showed that treatment emergent adverse event occurred in 30(15.6%) patients in TEL/AML/CHTD group and 18 (9.5%) patients in TEL/AML group. Treatment related adverse events occurred in 20(10.4%) patients of TEL/AML/CHTD group and 10(5.3%) patients of TEL/AML group.…”

“…Most of the studies regarding combination therapy prefer lower dose of chlorthalidone as 3.125–12.5 mg combination in dual 25 or triple therapy. 26 , 27 , 28 , 29 …”

Leukocyte Telomere Length as a Molecular Biomarker of Coronary Heart Disease

“…Thus, CAD and arterial hypertension [ 76 , 77 , 78 , 79 , 80 , 81 ], CAD and atrial fibrillation [ 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 ] and CAD and vascular cognitive disorders [ 92 , 93 , 94 , 95 ] are common comorbid conditions with overlap syndrome. Therefore, the study of LTL seems important not only in isolated CAD and AMI but also in these syndromes of mutual aggravation.…”

“…Nevertheless, this trend could be clarified by new, large, and multicenter studies with a similar design in the future. Thus, CAD and arterial hypertension [76][77][78][79][80][81], CAD and atrial fibrillation [82][83][84][85][86][87][88][89][90][91] and CAD and vascular cognitive disorders [92][93][94][95] are common comorbid conditions with overlap syndrome. Therefore, the study of LTL seems important not only in isolated CAD and AMI but also in these syndromes of mutual aggravation.…”